Table 1.
Baseline Characteristics of the sample (n=1619)
| Characteristic | n/N (%) or mean (range) | Those with fall at follow up (n=425) | Those without fall at follow up (n=1194) | p-value |
|---|---|---|---|---|
| Caucasian: | 1127/1,619 (69.6) | 319 (75.1) | 808 (67.7) | 0.005 |
| Men: | 529/1,619 (32.7) | 113 (26.6) | 416 (34.8) | 0.002 |
| Mean Age: years (range) | 62 (45–89) | 64 (45–89) | 62 (45–85) | 0.001 |
| Mean BMI (kg/m2): (range) | 30.8 (17.1–65.8) | 31.2 (18.8–54.0) | 30.6 (17.1–65.8) | 0.108 |
| Current Smokers: | 223/1,619 (13.8) | 49 (11.5) | 174 (14.6) | 0.118 |
| Current Alcohol use: | 319/1,619 (19.7) | 71 (16.7) | 248 (20.8) | 0.070 |
| History of Narcotic use1: | 50/1,613 (3.1) | 23 (5.5) | 27 (2.3) | 0.001 |
| History of Sleep Aids: | 607/1,611 (37.7) | 178 (42.1) | 429 (36.1) | 0.030 |
| History of Bisphosphonate use: | 96/1,614 (6.0) | 29 (6.9) | 67 (5.6) | 0.358 |
| History of Vitamin D use: | 373/1,561 (23.9) | 105 (25.9) | 268 (23.2) | 0.280 |
| Reported Lung Problems2: | 311/1,619 (19.2) | 109 (25.7) | 202 (16.9) | <.0001 |
| Reported Diabetes: | 258/1,619 (15.9) | 79 (18.6) | 179 (15.0) | 0.082 |
| Reported Neurologic Problems3: | 122/1,619 (7.5) | 47 (11.1) | 75 (6.3) | 0.002 |
| Reported Blindness: | 67/1,619 (4.1) | 24 (5.7) | 43 (3.6) | 0.069 |
| Reported history of Cancer: | 175/1,618 (10.8) | 45 (10.6) | 130 (10.9) | 0.876 |
| Median CES-D4 : (range) | 6.06 (0–53) | 7.21 (0–53) | 5.66 (0–46) | 0.001 |
| Falls at baseline: | 352/1,616 (21.8) | 146 (34.4) | 206 (17.3) | <.0001 |
| Symptomatic Knee OA: | 321/1590 (20.2) | 111 (26.5) | 210 (17.9) | 0.001 |
| Symptomatic Hip OA: | 196/1518 (12.9) | 78 (19.7) | 118 (10.5) | <.0001 |
| 1 Symptomatic Lower Extremity Joint | 218/1498 (14.5) | 72/392 (18.4) | 146/1106 (13.2) | <.0001 |
| 2 Symptomatic Lower Extremity Joints | 166/1498 (11.1) | 63/392 (16.1) | 103/1106 (9.3) | |
| 3–4 Symptomatic Lower Extremity Joints | 45/1498 (3.0) | 19/392 (4.9) | 26/1106 (2.4) | |
| Falls at follow-up time point: | 425 (26.3) | - | - |
1
Defined as self-reported narcotic use for > 2 weeks (dichotomous)
2
Includes patient report of chronic bronchitis, emphysema or other chronic lung trouble (dichotomous)
3
Includes patient report of multiple sclerosis, stroke, epileptic seizures or convulsions, paralysis of any kind, or Alzheimer’s disease
4
Center for Epidemiologic Studies Depression scale (continuous [0–60], higher scores=more depressive symptoms)